Drug Kickback Ruling Will Make FCA Liability Harder To Prove
In U.S. v. Regeneron Pharmaceuticals Inc., decided by the U.S. Court of Appeals for the First Circuit on Feb. 18, the government alleged that the company violated the Anti-Kickback Statute by covering patient...To view the full article, register now.
Already a subscriber? Click here to view full article